20 January 2020 | News
Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus
image credit- shuttershock.com
Japan based Astellas Pharma Inc. has successfully completed the previously announced acquisition of Audentes Therapeutics, Inc. (“Audentes”), through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition Corp. (“Asilomar”) for all of the issued and outstanding shares of common stock of Audentes for a price of US$60.00 per share net to the seller in cash (“Tender Offer”) and the subsequent merger of Asilomar with and into Audentes.
“The Audentes team is comprised of highly talented individuals with world-class expertise in AAV-based genetic medicines manufacturing, research and development, and commercialization,” said Kenji Yasukawa, President and CEO, Astellas. “We look forward to working with Audentes to accelerate and expand our efforts in genetic medicines, and to leverage this innovative science to create significant value for patients.”
Within Astellas, Audentes will operate as a wholly-owned subsidiary, and will serve as the Center of Excellence for the newly created Genetic Regulation Primary Focus, providing leadership for AAV pipeline advancement through commercialization, manufacturing expansion, and next-generation research initiatives. Effective immediately, Natalie C. Holles has been appointed President and Chief Executive Officer of Audentes.
Astellas is currently reviewing the impact that the completion of the transactions described above may have on its consolidated business forecast for the current fiscal year and will make any necessary disclosure in accordance with applicable requirements.